Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study

医学 美罗华 泼尼松龙 内科学 血管炎 胃肠病学 不利影响 抗中性粒细胞胞浆抗体 强的松 皮质类固醇 甲基强的松龙 维持剂量 外科 淋巴瘤 疾病
作者
Shunsuke Furuta,Daiki Nakagomi,Y Kobayashi,Masaki Hiraguri,Takao Sugiyama,Koichi Amano,Takeshi Umibe,Hajime Kono,Kazuhiro Kurasawa,Yasuhiko Kita,Ryutaro Matsumura,Yuko Kaneko,Keita Ninagawa,Keiju Hiromura,Shin‐ichiro Kagami,Yosuke Inaba,Hideki Hanaoka,Kei Ikeda,Hiroshi Nakajima
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:83 (1): 96-102 被引量:12
标识
DOI:10.1136/ard-2023-224343
摘要

Objectives The LoVAS trial reported non-inferiority in remission induction rates between the reduced-dose and conventional high-dose glucocorticoid regimens plus rituximab for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 6 months; however, maintenance glucocorticoid requirements and long-term outcomes are unknown. Methods A total of 140 patients with new-onset ANCA-associated vasculitis without severe glomerulonephritis or alveolar haemorrhage were randomised to receive reduced-dose prednisolone (0.5 mg/kg/day) plus rituximab (375 mg/m 2 /week×4) or high-dose prednisolone (1 mg/kg/day) plus rituximab. After achieving remission, patients received the rituximab maintenance therapy (1 g/6 months). Results A total of 134 patients were analysed. Among patients who achieved remission with the protocolised treatments, the majority of patients in the reduced-dose group (89.7%) and 15.5% in the high-dose group discontinued prednisolone (median time to withdrawal, 150 and 375 days, respectively). During 24-month trial period, two patients in the reduced-dose group (2.8%) died, while five patients in the high-dose group (7.6%) died (p=0.225). Relapse occurred in nine patients in the reduced-dose group (13.0%) (two major and seven minor) and five in the high-dose group (7.6%) (two major and three minor) (p=0.311). Serious adverse events (SAEs) were less frequent in the reduced-dose group (36 events in 19 patients, 27.5%) than in the high-dose group (54 events in 30 patients, 46.2%) (p=0.025). Conclusion At 24 months, frequencies of relapse did not differ between the groups, and SAEs were less frequent in the reduced-dose group due to the lower event rate in the 6-month induction phase. The bias to myeloperoxidase-ANCA positivity (85.8%) in the trial population should be noted. Trial registration number NCT02198248 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
2秒前
暴躁小龙发布了新的文献求助10
3秒前
张润泽完成签到 ,获得积分10
3秒前
4秒前
文档发布了新的文献求助10
4秒前
5秒前
7秒前
8秒前
8秒前
9秒前
10秒前
10秒前
烟花应助zwk采纳,获得10
12秒前
蔡芝艳关注了科研通微信公众号
12秒前
YI完成签到,获得积分10
15秒前
15秒前
大个应助科研通管家采纳,获得10
16秒前
16秒前
充电宝应助科研通管家采纳,获得10
17秒前
SYLH应助科研通管家采纳,获得20
17秒前
Ava应助科研通管家采纳,获得10
17秒前
丘比特应助科研通管家采纳,获得10
17秒前
情怀应助科研通管家采纳,获得10
17秒前
Hello应助科研通管家采纳,获得10
17秒前
Owen应助科研通管家采纳,获得10
17秒前
17秒前
su发布了新的文献求助10
19秒前
钟垠州完成签到 ,获得积分10
19秒前
19秒前
活力的妙之完成签到 ,获得积分10
19秒前
丘比特应助只想困瞌睡采纳,获得10
19秒前
小宋发布了新的文献求助10
20秒前
笃定发布了新的文献求助30
22秒前
淡墨完成签到,获得积分10
23秒前
今后应助清漪采纳,获得10
23秒前
zwk发布了新的文献求助10
24秒前
27秒前
鹿君浩发布了新的文献求助10
28秒前
28秒前
小宋完成签到,获得积分10
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158